Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats

Molecular Vision

Volumn 16, Issue , 2010, Pages 1525-1537

  Saraswat, Megha ^a   Suryanarayana, Palla ^a   Reddy, Paduru Yadagiri ^a   Patil, Madhoosudan A ^a   Balakrishna, Nagalla ^a   Reddy, Geereddy Bhanuprakash ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GINGER EXTRACT; GLUCOSE; INSULIN; POLYOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; FOOD INTAKE; GINGER; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LENS; MALE; NONHUMAN; OSMOTIC STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; SLIT LAMP; WISTAR RAT;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CATARACT; DIABETES COMPLICATIONS; DISEASE PROGRESSION; EYE PROTEINS; FEEDING BEHAVIOR; GINGER; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; L-IDITOL 2-DEHYDROGENASE; LENS, CRYSTALLINE; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; SOLUBILITY;

EID: 77955704177     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Mohan V, Sandeep S, Deepa R. B. Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007; 125:217-30.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53.
3. Stanga PE, Boyd SR, Hamilton AM. Ocular manifestations of diabetes mellitus. Curr Opin Ophthalmol 1999; 10:483-9.
4. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003; 290:2057-60.
5. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end products: a review. Diabetologia 2001; 44:129-46.
6. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48:1-9.
7. Ahmed N. Advanced glycation end products-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67:3-21.
8. Nagaraj RH, Sady C. The presence of a glucose-derived Maillard reaction product in the human lens. FEBS Lett 1996; 382:234-8.
9. Cherian M, Abraham EC. Glycation of human lens crystallins effect of age and aspirin treatment. Ophthalmic Res 1993; 25:349-54.
10. van Boekel MA, Hoenders HJ. Glycation of crystallins in lenses from aging and diabetic individuals. FEBS Lett 1992; 314:1-4.
11. Luthra M, Balasubramanian D. Nonenzymatic glycation alters protein structure and stability. A study of two eye lens crystallins. J Biol Chem 1993; 268:18119-27.
12. Kumar MS, Reddy PY, Kumar PA, Surolia I, Reddy GB. Effect of dicarbonyl-induced browning on α crystallin chaperonelike activity: physiological significance and caveats of in vitro aggregation assays. Biochem J 2004; 379:273-82.
13. Kumar PA, Kumar MS, Reddy GB. Effect of glycation on alpha-crystallin structure and chaperone-like function. Biochem J 2007; 408:251-8.
14. Beswick HT, Harding JJ. Conformational changes induced in lens alpha- and gamma-crystallins by modification with glucose 6-phosphate. Implications for cataract. Biochem J 1987; 246:761-9.
15. Vlassara H. Advanced glycation end products and atherosclerosis. Ann Med 1996; 28:419-26.
16. Shuvaev VV, Laffont I, Serot JM, Fuiji J, Taniquchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001; 22:397-402.
17. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46:223-34.
18. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41:26-9.
19. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS Design and baseline characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20:493-510.
20. Swamy-Mruthinti S, Green K, Abraham EC. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp Eye Res 1996; 62:505-10.
21. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51:2826-32.
22. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P. An agent cleaving glucosederived protein rosslinks in vitro and in vivo. Nature 1996; 382:275-8.
23. Saraswat M, Reddy PY, Muthenna P, Reddy GB. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br J Nutr 2009; 101:1714-21.
24. Kumar PA, Reddy PY, Srinivas PNBS, Reddy GB. Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of α-crystallin chaperone activity. J Nutr Biochem 2009; 20:553-62.
25. White B. Ginger: An Overview. Am Fam Physician 2007; 75:1689-91.
26. Ojewole JA. Analgesic. Antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) Rhizomes (Zingiberaceae) in mice and rats. Phytother Res 2006; 20:764-72.
27. Al-Amin ZM, Thomson M, Al-Qattan KK, Peltonen-Shalaby R, Ali M. Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. Br J Nutr 2006; 96:660-6.
28. Weidner MS, Sigwart K. The safety of ginger extract in the rat. J Ethnopharmacol 2000; 73:513-20.
29. Islam MS, Choi H. Comparative effects of dietary ginger (Zingiber officinale) and garlic (Allium sativum) investigated in a type 2 diabetes model of rats. J Med Food 2008; 11:152-9.
30. Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K, Reddy GB. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 2005; 46:2092-9.
31. Zelenka PS, Gao CY, Saravanamuthu SS. Preparation and culture of rat lens epithelial explants for studying terminal differentiation. J Vis Exp 2009; 31:1519.
32. Suryanarayana P, Saraswat M, Petrash JM, Reddy GB. Emblica officinalis and its enriched tannoids delay streptozotocininduced diabetic cataract in rats. Mol Vis 2007; 13:1291-7.
33. Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL, Ahren B. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol 1998; 274:R1482-91.
34. Sipols AJ, Baskin DG, Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995; 44:147-51.
35. Sahu A, Sninsky CA, Kalra PS, Kalra SP. Neuropeptide-Y concentration in microdissected hypothalamic regions and in vitro release from the medial basal hypothalamus-preoptic area of streptozotocin-diabetic rats with and without insulin substitution therapy. Endocrinology 1990; 126:192-8.
36. Almdal TP, Vilstrup H. Effects of streptozotocin-induced diabetes and diet on nitrogen loss from organs and on the capacity of urea synthesis in rats. Diabetologia 1987; 30:952-6.
37. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-20.
38. Saraswat M. Evaluation of aldose reductase inhibitors & antiglycating agents from dietary sources: implication in the prevention of secondary complications of diabetes (cataract). PhD Thesis, Osmania University, Hyderabad, 2009.
39. Nagaraj RH, Shipanova IN, Faust FM. Protein cross-linking by the Maillard reaction. Isolation, characterization, and in vivo detection of a lysine-lysine cross-link derived from methylglyoxal. J Biol Chem 1996; 271:19338-45.
40. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi SN. ε(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996; 35:8075-83.
41. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997; 324:565-70.
42. Chang KC, Paek KS, Kim HJ, Lee YS, Yabe-Nishimura C, Seo HG. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 2002; 61:1184-91.
43. Nakamura N, Obayashi H, Fujii M, Fukui M, Yoshimori K, Ogata M, Hasegawa G, Shigeta H, Kitagawa Y, Yoshikawa T, Kondo M, Ohta M, Nishimura M, Nishinaka T, Nishimura CY. Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radic Biol Med 2000; 29:17-25.
44. Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac J Clin Nutr 2008; 17:558-65.
45. King H, Aubert R, Herman W. Global burden of diabetes, 1995- 2025, Prevalence numerical estimates and projections. Diabetes Care 1998; 21:1414-31.
46. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the 'metabolic memory', the new challenge of diabetes. Diabet Med 2007; 24:582-6.
47. Kyselova Z, Stefek M, Bauer V. Pharmacological prevention of diabetic cataract. J Diabetes Complications 2004; 18:129-40.
48. Kinoshita JH. Mechanisms initiating cataract formation. Proctor Lecture. Invest Ophthalmol Vis Sci 1974; 13:713-24.
49. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol 2008; 46:409-20.
50. Kato A, Higuchi Y, Goto H, Kizu H, Okamoto T, Asano N, Hollinshead J, Nash RJ, Adachi I. Inhibitory effects of Zingiber officinale Roscoe derived components on aldose reductase activity in vitro and in vivo. J Agric Food Chem 2006; 54:6640-4.